SYSTEMATIC REVIEW article
Front. Med.
Sec. Ophthalmology
This article is part of the Research TopicAdvances in Ocular Autoimmune DiseasesView all 9 articles
Meibomian gland dysfunction in patients with thyroid-associated ophthalmopathy: a systematic review and meta-analysis
Provisionally accepted
- 1Guangzhou Panyu Bright Eye Hospital, Guangzhou, China
- 2Heyou Hospital, Foshan, China
- 3Zhongshan Torch Development Zone People's Hospital, Zhongshan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Background: Meibomian gland dysfunction (MGD) secondary to thyroid-associated ophthalmopathy (TAO) represents a significant pathogenic mechanism in dry eye disease. This study provides the first systematic review and meta-analysis of MGD indicators in TAO. Methods: The study protocol was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) (Registration ID: CRD420251020327) before data extraction. Following PRISMA and MOOSE guidelines, a systematic search was conducted across PubMed, Embase, Web of Science, Scopus, Ovid Medline, and Cochrane from inception through March 27, 2025. Fourteen studies met the inclusion criteria. Key indicators included lipid layer thickness (LLT), meiboscore, meibum quality, first non-invasive tear film break-up time (NITBUT-f), average non-invasive tear film break-up time (NITBUT-avg), tear break-up time (TBUT), meibomian gland dropout area in the upper (MGDU) and lower eyelids (MGDL), and in vivo confocal microscopy (IVCM) markers (meibomian gland acinar density [MAD], meibomian gland acinar longest diameter [MALD], meibomian gland acinar shortest diameter [MASD]). Risk of bias was assessed using the AHRQ checklist or NOS. Meta-analysis was performed with Review Manager 5.4.1 and Stata 16.0. Publication bias was assessed using Egger's test and funnel plots. Fixed-effects models were used in the absence of significant heterogeneity (P > 0.10 or I2 < 50%); otherwise, random-effects models were applied. Results: Thirteen studies (813 TAO eyes, 522 controls) were included in the meta-analysis. Quality assessment revealed moderate-to-high methodological rigor across studies. Patients with TAO exhibited significantly worse meibomian gland indicators compared to controls: higher LLT, increased meiboscore, greater eyelid gland dropout (MGDU, MGDL), and shorter tear film stability (NITBUT-f, TBUT). IVCM markers indicated meibomian acinar enlargement (MALD, MASD). Active TAO was associated with higher LLT compared to inactive TAO. Significant heterogeneity was observed in several outcomes, including meiboscore, NITBUT-f, TBUT, MGDL, and MASD comparisons. Conclusions: Despite the limited number of studies and small sample sizes, TAO is linked to meibomian gland atrophy, acinar dilation, and tear film instability. Active disease is associated with more pronounced lipid layer abnormalities. Targeted evaluation and management of MGD are crucial to mitigate TAO-associated ocular surface morbidity and improve patient quality of life.
Keywords: Thyroid-associated ophthalmopathy, Meibomian gland dysfunction, dry eye, Meibomian gland, Meta-analysis
Received: 19 Sep 2025; Accepted: 23 Oct 2025.
Copyright: © 2025 Lu, Li and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tulong Lin, lintulong@outlook.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.